Capricor Therapeutics (CAPR) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 32.0% versus a gain of 8.1%. Over five years, CAPR leads with a +122.6% price change compared with +118.8% for DMAC. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $441.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | DMAC |
|---|---|---|
| Share price | $7.59 | $8.25 |
| Market cap | $441.30M | $445.15M |
| 1-day change | +0.80% | +2.87% |
| YTD return | -73.70% | +3.64% |
| 1-year return | +32.00% | +8.13% |
| 5-year return | +122.58% | +118.83% |
| EPS (TTM) | $-2.65 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-105.04M | $-32.77M |
| 52-week high | $40.37 | $11.00 |
| 52-week low | $2.96 | $5.25 |
| Distance from 52-week high | -81.20% | -25.00% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +259.03% | +96.97% |
| Average volume | 4.73M | 210.46K |
| Shares outstanding | 58.14M | 53.96M |
| Employees | 231 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed DMAC by 23.9 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
CAPR vs DMAC FAQ
Which is bigger, Capricor Therapeutics or DiaMedica Therapeutics?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $441.30M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, CAPR or DMAC?
CAPR returned +32.00% over the past 12 months, compared with +8.13% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and DiaMedica Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.